

terbinafine 25 mg mL Oral Suspension

Department of Pharmacy

Batch No:	

Ingredients	Mfr	Lot #	Expiry Date	Quantity	Measured	Checked
terbinafine 250mg Tablets	Novartis/PMS			10		
ORA-Blend	Perrigo			q.s.100 mL		

Additional Information:

_			
		pm	nt
Εч	u	911	

mortar and pestle graduated measure

glass stirring rod

Procedure:

Follow your Dept. procedures for risk assessment/training/PPE/equipment/facilities/NAPRA level

- 1. Crush tablets in the mortar to a fine powder with a pestle.
- 2. Add a small amount of vehicle to powder and levigate into a smooth paste. Continue to levigate as vehicle is added in small amounts until a liquid is formed.
- 3. Transfer liquid contents from mortar to graduate.
- 4. Use a small amount of vehicle to rinse mortar and add it to graduate.
- 5. Use vehicle to q.s. to the final volume. Stir well.
- 6. Transfer to amber bottle and label.

Quality Control:

Expected Product Appearance	Additional Notes
White to light pink suspension	

Storage:	Room temperature
Packaging:	Amber glass/plastic PET bottles
BUD:	42 days

Sample Label:

SickKids	terbinafine 25 mg/mL Oral Suspen	sion
THE HOSPITAL FOR SICK CHILDREN	Lot:	BUD:
Department of Pharmacy	Room Temperature	Shake Well

Date Made/Prepared By/Checked By:		

Reference:

 Abdel-Rahman SM et al. Stability of terbinafine HCL in an extemporaneously prepared oral suspension at 25 ant 4C. Am J Health-Syst Pharm. 1999;56:243-5

Formulation Reviewed: October, 2020

Disclaimer: The information in this compounding and preparation worksheet was developed for in-house use only by The Hospital for Sick Children ("SickKids") and its staff. While SickKids endeavours to keep this information up to date and accurate, patient circumstances will vary and some information may become outdated as a result of recent medical developments following the time of printing. Any reliance you place on such information is therefore strictly at your own risk. Please note that the doses provided do not necessarily conform to the manufacturer's recommendations, and formularly drugs may not be licensed for use in children. The reader is cautioned to check the product information sheet provided by the manufacturer, and to verify indications, contraindications and recommended dosages. SickKids make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, or suitability of the information and related products contained in this worksheet for any purpose. SickKids accepts no responsibility for the reader's use, misuse or misinterpretation of the information, and does not promise success in achieving any desired result. In no event will SickKids be liable for any damage, liability or loss or for any indirect, incidental or consequential damages arising from the use of this information.